| Autor: |
Farhad Shahi, Associate Professor, Farahnaz Vafaeezadeh, Post doctoral fellowship, Nafiseh Ansarinejad, Associate Professor, Alireza Ahmadi, Post doctoral fellowship, Ali Shahriari-Ahmadi, Associate Professor, Alireza Ghazizadeh, Associate Professor, Hassanali Vahedian Ardakani, Associate Professor, Mohammad Reza Ravanbod, Associate Professor, Sharareh Seifi, Associate Professor, Mohammad Foratyazdi, Associate Professor, Seyed Asadollah Mousavi, Associate Professor, Mansour Rajabi Vahid, Associate Professor, Hossein Rahimi, Associate Professor, Mohammad Seghatoleslami, Post doctoral fellowship, Seyed Mohsen Razavi, Associate Professor, Amir Houshang Pourkhani, Associate Professor, Davoud Babakhani, Post doctoral fellowship, Nassim Anjidani, Pharm. D. |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Current Therapeutic Research, Vol 96, Iss , Pp 100659- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
0011-393X |
| DOI: |
10.1016/j.curtheres.2021.100659 |
| Popis: |
ABSTRACT: Background: Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non–small cell lung cancer, and prostate cancer. Objective: This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel. Methods: Patients who received Alvotere as a part of their chemotherapy regimen were enrolled in this Phase IV, observational, multicenter, open-label study. Alvotere was administrated as a single agent or in combination with other chemotherapy agents. Safety parameters in each cycle were assessed, and the related data were recorded in booklets. Findings: A total of 411 patients with different types of cancers were enrolled from 25 centers in Iran. The most common malignancies among participants were breast cancer (49.88%), followed by gastric cancer (22.63%). Participants’ mean age was 53.33 years, and the mean total dose used in each cycle was 132 mg. According to the results, 341 patients experienced at least 1 adverse event, that the most common was alopecia (41.12%). In total, 92 (22.38%) patients had at least 1 adverse event of grade 3 or 4, and 25 (6.08%) patients showed 54 serious adverse events, which the causality assessment for all was possibly related to Alvotere. There was a significant difference between men and women in the incidence of skin and subcutaneous tissue disorders (55.63% in women vs 41.73% in men; P = 0.009). Also, the incidence of gastrointestinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, hepatic enzymes increase, and fluid retention was significantly higher (P < 0.05) in patients receiving anthracyclines in their chemotherapy regimens. Conclusions: The findings of this open-label, observational, multicenter, postmarketing surveillance showed that Alvotere appears to have an acceptable safety profile in Iranian cancer patients receiving chemotherapeutic regimens. (Curr Ther Res Clin Exp. 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals, Inc. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
